Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer
Key Points
Key Points
- This guideline focuses on patients with advanced, recurrent, or metastatic prostate cancer and noncastrate testosterone levels whose disease is not yet castration-resistant, including those with biochemical recurrence only.
- The future of noncastrate advanced, recurrent, or metastatic prostate cancer care is predicted to include highly personalized treatment plans based on advanced genetic testing, next generation imaging, and the availability of highly predictive biomarkers.
- This targeted update is driven by results from recent Phase III clinical trials (ARASENS, PEACE-1, ENZAMET, and ARCHES) and two recent meta-analyses.
Treatment
...Treatm...
...Initial Treatment...
...1.0(Updated) Docetaxel, abiraterone, enzalutamide,...
...ANDROGEN...
...ecommendation 1.1(Updated) For patients wi...
...mmendation 1.11(New) For patients...
...ndation 1.15(New) For patients with de novo meta...
...1.16(New) The recommended regimen for...
....2(Updated) For patients with low-volume metastati...
...ecommendation 1.3(Updated) For patie...
...ADT PLUS ABIRATERONE...
...commendation 1.4For patients with h...
...ommendation 1.5For patients with low-risk...
...ion 1.6The recommended regimen for...
AD...
...mendation 1.7(Updated) ADT plus enza...
...on 1.8(Updated) The recommended regimen f...
...ADT PLUS A...
...ion 1.9ADT plus apalutamide should also be offe...
...mendation 1.95(Updated) The recommended regimen fo...
...Combination...
...ion 2.1ADT plus abiraterone and prednisolone s...
...ion 2.2In resource-constrained setting...
...Early And...
...ecommendation 3.1Early (immediate) AD...
...Intermittent Androgen D...
...on 4.1Intermittent therapy may be offer...
...1. Initial Management of Noncastrate Metastatic...